Actualités

By Karen Roman Redwire Corporation (NYSE: RDW) said it designated Paul Reichert and Niki Werkheiser to serve at strategic advisory roles at Space Microgravity Development (SpaceMD), Redwire’s venture company focused […]

For shareholders, the coming year isn't about a small gain or loss but a potential journey to one of two very different destinations.

MRK trades above its 50- and 200-day SMAs as pipeline progress, acquisitions and Keytruda strength offset patent and vaccine headwinds.

While rivals scramble to replace lost revenue, Lilly is opening an unprecedented gap by being a “contrarian,” as one expert says.

Merck (MRK) concluded the recent trading session at $126.78, signifying a -2.15% move from its prior day's close.

Before the share price caught on, the drugmaker was dealing with a problem most companies only dream of, and it was the clearest sign a surge was building.

Gilead wins FDA approval to expand Trodelvy into first-line mTNBC, boosting its market reach and strengthening its oncology growth strategy.

Johnson & Johnson stock is Monday's IBD Stock Of The Day. The medical bellwether will report its June-quarter earnings next week.

Stock Market Today: The Dow Jones index fell Monday, while tech futures rallied. Micron stock and Sandisk rebounded in premarket trading.

8.39am: Airlines and pubs in good mood Shares in easyJet have flown almost 10% higher to 610p but are still well below the 690p potential offer price. Sector peer Jet2 is up 3.8% too, while long-haul peer IAG has risen 2.1%. The FTSE 100 and FTSE 250 are both on the front foot, up...

Schwab U.S. Dividend Equity ETF (NYSEARCA:SCHD) pays a quarterly distribution from roughly 100 quality-screened U.S. dividend stocks. The fund holds $71.6 billion in assets at an expense ratio of just 0.06%, and it tracks the Dow Jones U.S. Dividend 100 Index, which requires 10 consecutive years of dividend payments and screens on cash flow to ... Six Dividend Aristocrats Keeping SCHD’s Income Stream Bulletproof This Year

Merck (NYSE:MRK) reported positive Phase 3 results for tulisokibart, an anti-TL1A monoclonal antibody in moderate-to-severe ulcerative colitis. The company announced new FDA approvals for KEYTRUDA-based regimens in triple-negative breast cancer and muscle-invasive bladder cancer. Regulatory authorities in the EU also cleared additional KEYTRUDA combinations in early-stage oncology settings. For investors tracking NYSE:MRK, these updates sit at the core of what drives long term value for a...

Moderna expands beyond vaccines while Recursion bets on AI-driven drug discovery, each with distinct risks, partnerships, and financial profiles.

Moderna surges 33.5% after the company outlines plans to expand its mRNA platform beyond vaccines into oncology, autoimmune diseases and cell therapies.

Healthcare stocks were higher late Thursday afternoon, with the NYSE Healthcare Index and the State

Merck stock is in a buy zone after hitting a new high. Fellow Dow stock JPMorgan Chase and Amphenol are both trading around entry points.

Healthcare stocks were higher Thursday afternoon, with the NYSE Healthcare Index rising 2% and the S

The healthcare giant raised its outlook for the year, yet the market is holding back its reward, creating a tense waiting game for investors.

Five of the biggest names in American pharma just got a deadline from Washington. The House Select Committee on China sent letters this week to Merck (MRK), AbbVie (ABBV), Eli Lilly (LLY), Pfizer (PFE), and Bristol Myers Squibb (BMY), Reuters reported. Lawmakers want each company to explain ...

Merck cited business reasons for the discontinuation of the investigational drug.

Merck & Co., Inc. (NYSE:MRK) is one of billionaire Cliff Asness’ top 10 healthcare stock picks. On June 25, Merck & Co., Inc. (NYSE:MRK) announced that the FDA approved both KEYTRUDA and KEYTRUDA QLEX each in combination with Gilead’s Trodelvy as a first-line treatment for adult patients with unresectable locally advanced or metastatic triple-negative breast […]

Bristol Myers Squibb trades at a deep discount, while Johnson & Johnson boasts higher margins and a broader reach. How do their financials and risks stack up?

The healthcare giant is making waves, but its true value for investors lies in how little it moves with the market.

Healthcare stocks were lower late Tuesday afternoon, with the NYSE Healthcare Index decreasing 0.9%

U.S. lawmakers have opened national security investigations into Merck's clinical trial activities in China. The probes focus on trials conducted in politically sensitive regions, including Xinjiang, and at hospitals linked to the Chinese military. Key concerns include intellectual property protection, ethical oversight, and the handling of sensitive biotechnology data. Merck, listed as NYSE:MRK, is a large global pharmaceutical company with a heavy focus on prescription medicines,...

A bipartisan group of United States lawmakers has opened national security investigations into whether five major pharmaceutical companies, including Merck and AbbVie, were involved in clinical trials conducted in China that may have supported the country’s military capabilities, according to a...

Merck's (MRK) upcoming phase 3 OptiTrop-Lung06 readout could establish SAC-TMT as a chemotherapy rep

A bipartisan House committee wants details on hundreds of clinical studies conducted at Chinese military facilities and in Xinjiang

Recursion harnesses AI for large-scale drug discovery, while Summit's betting on a single oncology candidate. How do their financials and risk profiles stack up?

AbbVie (ABBV) and Merck (MRK) are facing investigations by the China Select Committee of the US Hous